GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods

References

• U.S. Food and Drug Administration [internet]. Humira. Highlights of prescribing information; 2017 [cited 2018 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf.
   Google Scholar
• European Medicines Agency [internet]. Humira. Summary of product characteristics; 2017 [cited 2018 Nov 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf.
   Google Scholar
• Araujo FC, Goncalves J, Fonseca JE. Pharmacoeconomics of biosimilars: what is there to gain from them? Curr Rheumatol Rep. 2016;18(8):50.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Wu JJ, Puig L, et al. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. Br J Dermatol. 2017;177(6):1495–1502.
   PubMed Web of Science ®Google Scholar
• Gulacsi L, Pentek M, Rencz F, et al. Biosimilars for the management of inflammatory bowel diseases: economic considerations. Curr Med Chem. 2017 Apr 6. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Rencz F, Pentek M, Bortlik M, et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015;21(6):1728–1737.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [internet]. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance – non-clinical and clinical issues; 2015 [cited 2018 Nov 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf.
   Google Scholar
• U.S. Food and Drug Administration [internet]. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for Industry; 2015 [cited 2018 Nov 27]. Available from: www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
   Google Scholar
• McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther. 2012;91(3):405–417.
   PubMed Web of Science ®Google Scholar
• Holzmann J, Balser S, Windisch J. Totality of the evidence at work: the first U.S. biosimilar. Expert Opin Biol Ther. 2016;16(2):137–142.
   PubMed Web of Science ®Google Scholar
• Schiestl M, Roesli C. Development and analytical characterization of GP2017: A proposed adalimumab biosimilar. Am J Gastroenterol. 2016;111(S289):Abstract628.
   Google Scholar
• Kronthaler U, Fritsch C, Hainzl O, et al. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18(8):921–930.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lacour JP, Fowler JF Jr., et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623–631.
   PubMed Web of Science ®Google Scholar
• Wiland P. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab biosimilar (GP2017) with reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis. Arthritis Rheumatol. 2018;70(suppl):10.
   Google Scholar
• European Medicines Agency [internet]. Hyrimoz. Summary of product characteristics; 2018 [cited 2018 Nov 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004320/WC500252822.pdf.
   Google Scholar
• U.S. Food and Drug Administration [internet]. Hyrimoz. Highlights of prescribing information; 2018 [cited 2018 Nov 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf.
   Google Scholar
• Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–1629.
   PubMed Web of Science ®Google Scholar
• Tischer B, Patients’ and nurses’ preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer Adherence. 2018;12:1413–1424.
   PubMed Web of Science ®Google Scholar
• Vermeire S, D’Heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018;12:1193–1202.
   PubMed Web of Science ®Google Scholar
• Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14.
   PubMed Web of Science ®Google Scholar
• Muller-Ladner U, Flipo RM, Vincendon P, et al. Comparison of patient satisfaction with two different etanercept delivery systems. A randomised controlled study in patients with rheumatoid arthritis. Z Rheumatol. 2012;71(10):890–899.
   PubMed Web of Science ®Google Scholar
• Nader A, Beck D, Noertersheuser P, et al. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet. 2017;56(9):1091–1102.
   PubMed Web of Science ®Google Scholar
• Webster CJ, Woollett GR. Comment on. The end of phase 3 clinical trials in biosimilars development? [journal article]. BioDrugs. 2018;32(5):519–521.
   PubMed Web of Science ®Google Scholar
• Frapaise F. The end of phase 3 clinical trials in biosimilars development? BioDrugs. 2018;32(4):319–324.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spano F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–588.
   PubMedGoogle Scholar
• Chen ML, Lee SC, Ng MJ, et al. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000;68(5):510–521.
   PubMed Web of Science ®Google Scholar
• Ludescher B, Rommel M, Willmer T, et al. Subcutaneous adipose tissue thickness in adults - correlation with BMI and recommendations for pen needle lengths for subcutaneous self-injection. Clin Endocrinol (Oxf). 2011;75(6):786–790.
   PubMed Web of Science ®Google Scholar